Abstract
1035Background: Chemotherapy is dosed per mg/m2, which results in marked differences in inter-patient pharmacokinetics and toxicities. Tailored chemotherapy is based on dose adjustments based on individually recorded toxicities. Previous studies revealed superior survival outcomes with dose dense (DD) adjuvant regimens, but docetaxel was previously not considered suitable in a DD strategy. Health related quality of life (HRQoL) was a secondary endpoint in the Panther study. Methods: Patients with node positive breast cancer (BC), or with node negative BC > 20 mm, receptor negative (Er and Pr) Elston grade III, were randomized between tailored dose dense therapy (E 38-120 mg/m 2) C 450-1200 mg/m 2) followed by four cycles D75-100 mg/m 2) every second week (three weeks pause between EC and D), G-CSF support and prophylactic antibiotics), the ddtEC-D arm, vs. the control arm (three cycles F500 E100 C500 followed by three cycles of D100 every third week). HRQoL was evaluated using EORTC QLQ-C30 + EORTC QLQ-BR...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
